Introduction
Poly(methyl methacrylate) (PMMA) bone cement has been clinically implemented for a variety of applications including in orthopedic surgery as a temporary spacer following surgical debridement in two-part revision procedures [1] and at the Commercial antibiotic-filled bone cement typically contains either aminoglycosides (tobramycin and gentamicin) or glycopeptides (vancomycin). The concentration of antibiotic selected depends upon the intended use of the cement. In acute infections, more than 5% wt/wt of drug/cement is used, whereas less than 5% wt/wt of drug/cement is used for prophylactic applications. [14] While low doses of incorporated antibiotics may lead to the development of antibiotic-resistant bacteria over extended periods of time, [15] high doses have been shown to have a detrimental effect on the compressive [16] and shear [17] mechanical properties of the cement. The appropriate dosage is at the discretion of the surgeon.
PMMA cement is surgically prepared by mixing a prepoly mer powder with a liquid monomer, forming a dough which quickly solidifies, attaining temperatures of 60-80 °C in the process. [14] The high curing temperature results from the exothermic free-radical polymerization of PMMA, and necessitates that antibiotics used in bone cement be thermally stable so that they remain functional. This thermal stability requirement ultimately limits the range of antibiotics that can be incorporated into PMMA. Aminoglycosides (e.g., tobramycin and gentamicin) are one of the few classes of antibiotics compatible with PMMA that meet this requirement. [18] In addition to thermal stability, the selected antibiotic should be released at levels above the minimum inhibitory concentration upward of 1-2 months in order to prevent the occurrence of acute orthopedic infections and not negate cement mechanical robustness. [19] [20] [21] Acute orthopedic infections typically occur within the first three months following the procedure and are primarily caused by virulent Staphylococcus aureus (S. aureus), [21] therefore it is desirable to have a consistent antibiotic release from the implant during this time to prevent infection.
While aminoglycoside filled bone cement formulations are regularly used in clinical applications, they nevertheless have inherent limitations. Specifically, Moojen et al. found subtherapeutic release of gentamicin and tobramycin from PMMA spacers after 1 week (below minimum inhibitory concentration), [22] demonstrating limited utility for treatment of advanced infections. Beyond such transient release periods for incorporated therapeutics, PMMA has not demonstrated antibiotic refilling capabilities, meaning that there is limited and suboptimal window of time during which the drug-filled PMMA can treat infections once implanted. The lack of antibiotic refillability precludes PMMA from being utilized in the treatment of chronic or recurrent infections and necessitates the use of revision surgeries to treat delayed or complicated infections.
Various strategies have been attempted to improve upon the antibiotic release kinetics (i.e., amount of drug released and duration of release) from antibiotic-filled PMMA. To improve the permeability and subsequent antibiotic elution from PMMA, soluble porogens (e.g., xylitol) have been added as fillers to PMMA. [23, 24] Additionally, an antimicrobial peptide, Dhvar-5, has been incorporated into PMMA cement and was shown to enable a more consistent and prolonged release of gentamicin as well as increase the total amount of gentamicin released (relative to the amount of drug initially incorporated) by increasing the micro-porosity of the cement. [25] Yet, when manipulating the porosity and permeability of the PMMA, it is important to consider the delicate balance between the drug release characteristics of the cement and its mechanical properties, because voids in the cement act as stress risers.
Alternatively, various studies have added antibiotics with increased potency (i.e., antimicrobial activity) to PMMA. For example, linezolid has been incorporated into PMMA and demonstrated inhibition of methicillin-resistant S. aureus growth in vitro. [26] Additionally, rifampicin (RMP), which is highly potent against Staphylococci but impairs the mechanical strength of PMMA upon free-drug incorporation, has been encapsulated into alginate microcapsules and then incorporated into bone cement. [27] The alginate microcapsules in the cement have resulted in an enhanced antibacterial potency, increased elution of RMP relative to free RMP, and uncompromised mechanical properties of the cement. [27] While these strategies have resulted in increased antibiotic elution and have allowed for the incorporation of more potent antibiotics in PMMA, these approaches nevertheless demonstrate limited utility in the treatment of chronic or recurrent infections since they cannot be refilled with antibiotics after implantation.
Cyclodextrins (CDs) are cyclic oligosaccharides composed typically of 6 to 8 glucose units arranged in a ring, forming a torus structure containing a nonpolar interior pocket and a relatively polar exterior. [28] Insoluble polymerized CD has demonstrated the ability to form inclusion complexes (i.e., be "filled") with a variety of antibiotics including RMP, vancomycin, and erythromycin, resulting in an extended, affinity-based release when compared to release systems governed by diffusion alone (e.g., PMMA). [29] [30] [31] [32] Therefore, the incorporation of polymerized CD into PMMA may extend and enable more control over the drug release profile of the filled antibiotic. Furthermore, CD polymers have demonstrated thermal stability, improved tensile strength, and prolonged drug release following autoclave sterilization. [33] Thus, suggesting that heat generated during PMMA polymerization reaction is unlikely to negatively impact the properties of CD polymers since the extreme heat attained during autoclaving did not negatively impact the properties. CD polymers are also capable of being refilled with antibiotic once implanted, even in the presence of a mature biofilm, and refilled CD polymers have been shown to retain their antimicrobial activity. [34] The refilling ability of polymerized CD makes it an attractive candidate to incorporate into implanted medical devices, such as joint replacements, as it may allow infected implants covered in biofilm to be treated locally rather than invasively removed. [34] Therefore, in this work polymerized CD microparticles were selected to be incorporated into PMMA due to their extended affinity-based drug release [29] [30] [31] [32] and their refilling capacity. [34] The hypothesis of the present study was that incorporation of CD microparticles into PMMA bone cement would increase and prolong the effectiveness of incorporated antibiotics and enable drug refilling while reducing the impact of antibiotics on cement mechanics. In this work, polymerized CD microparticles were incorporated into PMMA in an effort to 1) improve the drug release properties of PMMA, 2) enable a wider variety of antibiotics to be incorporated into PMMA without compromising mechanical properties, and 3) to permit future drug refilling of PMMA following implantation. Insoluble polymerized CD microparticles were synthesized, filled with either gentamicin, tobramycin, or RMP, and then embedded into PMMA www.advancedsciencenews.com www.advhealthmat.de cement prepolymer as it cured. PMMA formulations with CD microparticles were compared against PMMA formulations with the same three antibiotics freely added in. Drug release and antimicrobial activity against gram-positive S. aureus were evaluated for each different formulation. S. aureus was selected as the model microorganism because most metallic implant infections are caused by Staphylococci strains. [35] The internal structure and porosity of PMMA cylinders was evaluated using micro-computed tomography (micro-CT) scans. Mechanical properties of PMMA cement with free antibiotic and RMPfilled CD microparticles were evaluated using unconfined compression testing. Finally, refilling studies of PMMA samples with empty (nondrug filled) CD microparticles with RMP were evaluated and compared to PMMA without CD microparticles. Figure 1 provides a graphical overview of the analyses carried out on bone cement samples.
Results

Zone of Inhibition Study (Free Drug and Drug-Filled CD Microparticles in PMMA Spherical Beads)
The antimicrobial activity of each antibiotic (RMP, gentamicin, tobramycin) added either freely or filled in CD microparticles (β-or γ-CD, 5 or 10 wt%) into PMMA spherical beads during polymerization was evaluated against S. aureus bacteria in triplicate. Figure 2 demonstrates that clinically used formulations (i.e., gentamicin or tobramycin freely added into PMMA) resulted in a very short duration of antibacterial activity (only ≈12 d of bacteria clearance). Meanwhile, RMP, an antibiotic currently incompatible with PMMA in its free state, was able to clear bacteria for a much more substantial duration of time (i.e., >100 d). Furthermore, the RMP zones of inhibition were significantly larger than those of gentamicin and tobramycin for all time points after 4 d (p < 0.05; except for days 5 and 12) .
This confirms the long-lasting and high potency of RMP against S. aureus. [27] Similar zone of inhibition studies were also carried out for PMMA spherical beads with antibiotic-filled CD (antibiotic-CD) microparticles. Figure 3 depicts the duration of antimicrobial activity of each of the three antibiotics filled into both types of CD (β-or γ-) in 5 or 10 wt%. The addition of 10 wt% RMP-CD microparticles (β-or γ-) to PMMA beads yielded antimicrobial activity for more than 60 d, making this formulation a potential candidate for the treatment of chronic osteomyelitis. [36] In the case of gentamicin and tobramycin filled PMMA beads, the incorporation of drug-filled CD microparticles (β-or γ-, 5 or 10 wt%) resulted in comparable antimicrobial activity to PMMA samples with the same drugs freely added in. As a control, zone of inhibition studies were also carried out for PMMA bead samples containing either 5 or 10 wt% of empty (nondrug filled) β-or γ-CD microparticles and it was determined that empty CD microparticles alone do not exhibit any antimicrobial activity (see Figure S1 , Supporting Information). Therefore, all of the antimicrobial activity was attributed to the presence of the antibiotics, rather than the CD microparticles.
Quantification and Activity of Drug Release Aliquots
Antibiotics released from PMMA spherical beads containing either free antibiotics or antibiotic-CD microparticles were
Adv. Healthcare Mater. 2018, 7, 1800812 Figure 1 . Schematic outlining the scope of the work. Two types of PMMA were synthesized (with free drug and antibiotic-filled CD microparticles) and PMMA samples were evaluated in a variety of studies including drug release, antimicrobial activity (zone of inhibition), wateruptake, micro-CT, mechanical compression, and refilling. www.advancedsciencenews.com www.advhealthmat.de collected at discrete time points over several weeks for gentamicin and tobramycin formulations. In an effort to validate the therapeutic efficacy of each of the release sample aliquots antimicrobial susceptibility testing was completed at each time point against S. aureus bacteria. [37] Figure 4 depicts the combined release and activity (antimicrobial susceptibility testing) plots for gentamicin and tobramycin both freely added into PMMA and complexed with different amounts of CD microparticles. The black line represents the normalized drug release profile (mass of drug released/mass of entire PMMA bead) and the red line indicates the antimicrobial zone of inhibition at each time point aliquot. Most of the plots demonstrated a relatively decreasing linear trend where the mass of drug released and antimicrobial activity decreased as the release time points increased, confirming the relationship between drug concentration and antimicrobial susceptibility. Generally, release aliquots were considered to have antimicrobial activity if their zone of inhibition (measured from the edge of the bead to edge of bacteria clearance) was >1 mm. When the antibiotics were freely added into PMMA beads (without CD) drug release and antimicrobial therapeutic activity was completed within 2-3 weeks with all samples. The release of RMP was not reported due to its high hydrophobicity and affinity for CD. [38] As a result, RMP exhibited little to no elution from PMMA in PBS with 10% dimethylformamide (DMF) and other slightly more hydrophobic sinks, such as Tween.
Compression Testing
To evaluate the mechanical strength of different PMMA formulations with and without CD microparticles, seven different cement groups (pure PMMA, PMMA with free tobramycin, PMMA with free RMP, PMMA with 5 or 10 wt% empty β-CD microparticles, and PMMA with 5 or 10 wt% RMP-β-CD www.advancedsciencenews.com www.advhealthmat.de microparticles) were selected and fabricated into cylinders (n ≥ 7). Gentamicin and tobramycin are currently added into PMMA in clinically used formulations, so mechanical properties of cement with CD microparticles filled with these drugs were not evaluated in this study, as it would not provide any new information. Figure S5 (Supporting Information) depicts the fabrication of the cylindrical PMMA samples in the custom poly(tetrafluoroethylene) (PTFE) two-part mold. During fabrication of the PMMA cylinders, PMMA was cured and removed from the mold after 1 h. However, in the case of PMMA with free RMP, curing and setting time were prolonged and the PMMA was not fully cured after 1 h. For this reason, PMMA cylinders with free RMP were kept in the mold for 20+ hours to ensure proper curing. Once cylinders were removed from the mold, they were machined and their compressive strength was evaluated according to ASTM standard procedures. Figure 5 depicts the load-displacement curves for all 7 groups (left) and the zoomed in curve for free RMP (right). Table 1 includes the quantification of the ultimate compressive strength, modulus, work to peak load, and strain to peak load.
Since there was a statistically significant difference between the compressive strength of pure PMMA and PMMA with free tobramycin (p = 0.0005) and both formulations are clinically used, cement with free tobramycin was used as the clinically relevant comparison for other antibiotic-incorporated experimental groups. Furthermore, PMMA with free tobramycin was selected as the control group since all of the experimental groups have antibiotics or additives (i.e., CD microparticles) incorporated into them. Addition of either 5 or 10 wt% empty β-CD microparticles resulted in a significant decrease in the compressive strength (5 wt%: 70.19 ± 1.44 MPa; 10 wt%: 67.37 ± 1.05 MPa) relative to free tobramycin (5 wt%: p = 3.2 × 10 −7 ; 10 wt%: p = 9.1 × 10 −10 ). Interestingly, addition of either 5 or 10 wt% RMP-β-CD microparticles resulted in a comparable compressive strength (5 wt%: 76.22 ± 2.27 MPa; 10 wt%: 75.80 ± 1.59 MPa) to free tobramycin (5 wt%: p = 0.21; 10 wt%: p = 0.064). Conversely, addition of free RMP resulted in a dramatic decrease in compressive strength (1.88 ± 0.15 MPa) relative to free tobramycin (77.03 ± 1.17 MPa). To be clinically useful, ASTM and ISO standards prescribe that bone cements must possess a compressive strength ≥ 70 MPa, and consequently all commercial bone cement products in use satisfy this requirement. [39] Therefore, the addition of RMP-β-CD microparticles helps to significantly improve the mechanical strength of PMMA relative to free RMP and yields a bone cement with Representative (closest to mean in terms of peak load) compressive load-displacement curves of PMMA cylinders. Experimental groups include pure PMMA, PMMA with free tobramycin, PMMA with free RMP, PMMA with 5 and 10 wt% empty β-CD microparticles, and PMMA with 5 and 10 wt% RMP-β-CD microparticles. Load-displacement curves of all groups superimposed (left) and zoomed in curve of free RMP cement (right). Comparable compressive strength was observed for pure PMMA, PMMA with free tobramycin, and PMMA with either 5 or 10 wt% RMP-β-CD microparticles. A decreased compressive strength resulted with addition of either 5 or 10 wt% empty-β-CD microparticles and the compressive strength dramatically decreased upon addition of free RMP. While most PMMA samples demonstrated plastic deformation characteristics, PMMA with free RMP demonstrated solely elastic deformation characteristics. Table 1 . Mechanical testing of cylindrical PMMA sample ultimate compressive strength, modulus, work to peak load, and strain to peak load. Statistically significant difference of samples relative to free tobramycin ( §), 5 wt% empty β-CD ( †), and 10 wt% empty β-CD ( ‡). 
Agarose Refilling Study (Pure PMMA vs CD Disks) and Quantification
The ability of polymerized β-CD disks to be refilled in situ with antibiotics was compared against the ability of PMMA spherical beads (without CD) to be refilled in the same manner. Figure 6 depicts the samples prior to being refilled with RMP (top) and after 48 h of in situ refilling (bottom). Presence of RMP is indicated by the red/orange color. Qualitatively, it was concluded that a larger amount of RMP was refilled into the β-CD disks compared to pure PMMA beads (without CD). This observation was quantitatively confirmed through a drug leaching study where RMP refilled samples were placed in DMF. Table 2 (top) includes the quantification of RMP refilling in β-CD disks compared to pure PMMA beads. β-CD disks were capable of being refilled with 16.55 ± 3.00 µg, nearly 15x more drug than what was refilled into pure PMMA (statistically significant; p = 0.012). When the mass of drug refilling was normalized against the mass of each polymer sample [mass of drug refilling (mg)/mass of PMMA bead (mg)], the difference in refilling between β-CD disks and pure PMMA was even more striking with β-CD disks refilling with nearly 80× more drug that what was possible in pure PMMA per mg of polymer sample (statistically significant; p = 0.0061).
Agarose Refilling Study (PMMA with CD Microparticles) and Quantification
Similar refilling studies were completed on PMMA spherical beads with embedded CD microparticles (β-or γ-, 5 or 10 wt%) in an effort to demonstrate that the addition of CD microparticles to PMMA cement induces a refilling property which is not inherently present in pure PMMA (see Figure 6 ). "Refilling," in the agarose model, was defined as being filled with antibiotic after implantation when both polymerization of PMMA is complete and the sample initially does not contain any drug when it is implanted. Figure 7 depicts the PMMA beads following 48 h of in situ refilling with RMP (γ-CD: top; β-CD: bottom) with increasing amounts of CD microparticles (i.e., no CD, 5 wt% CD, 10 wt% CD). It was observed that as the percentage of CD microparticles added into the PMMA beads increased, the amount of refilling noticeably increased, as qualitatively indicated by the presence of the red/orange color. DMF was used to leach out the drug from the refilled PMMA beads in an effort to quantify and confirm these observations. Table 2 (bottom) displays the quantification of RMP refilling in PMMA beads with either 5 or 10 wt% CD microparticles (β-or γ-) compared to pure PMMA samples (far left images). PMMA beads with 5 wt% of either β-or γ-CD were able to refill comparable amounts of RMP (1. Table 2 . Quantification of RMP refilling from agarose refilled polymer samples: pure PMMA versus β-CD disks (top) and pure PMMA versus PMMA with 5 and 10 wt% β-or γ-CD microparticles (bottom). Greater than 80× more RMP was refilled into β-CD disks per mg of polymer sample compared to pure PMMA beads. pure PMMA is attributed to passive drug diffusion into the surface of the PMMA bead, rather than CD-induced refilling processes. Therefore, the addition of either 5 or 10 wt% microparticles to PMMA beads increases and induces RMP refilling into PMMA beads.
Zone of Inhibition Study (refilled PMMA beads)
The antimicrobial activity of PMMA beads refilled with RMP was evaluated against S. aureus in a zone of inhibition study. 
Discussion
CD microparticles were incorporated into PMMA bone cement in an effort to improve upon antibiotic elution kinetics and induce antibiotic refilling without compromising the mechanical properties of PMMA. Analysis of the elution of aminoglycosides (i.e., gentamicin and tobramycin) from PMMA (with and without CD microparticles) indicated that their antimicrobial activity and release is completed within 2-3 weeks independent of the presence of CD microparticles (see Figure 4 ). This finding demonstrates that beyond 2-3 weeks, cement formulations containing aminoglycosides are no longer capable of releasing a therapeutically relevant amount of antibiotic (capable of clearing bacteria), but rather tend to release antibiotic at sub-therapeutic levels for a prolonged period of time promoting the development of drug-resistant bacteria. [40] The poor release kinetics and subsequent antimicrobial susceptibility to gentamicin and tobramycin further confirms the need to develop a PMMA antibiotic delivery system that is compatible with a widerrange of antibiotics (beyond aminoglycosides) and facilitates more controlled and prolonged release kinetics. While our drug release studies demonstrated a slight "burst" release of antibiotic early on, the high local concentration of antibiotic released initially is not anticipated to present a cytotoxicity concern. [41, 42] Previous studies have shown that gentamicin, tobramycin, and RMP do not have any direct detectable cytotoxicity toward primary human osteoblasts in high concentrations. [42] CD microparticles additionally enabled in situ refilling of PMMA following implantation. Substantial refilling was observed in PMMA with 10 wt% CD microparticles compared to essentially no refilling obtained with pure PMMA, demonstrating the capacity of PMMA containing CD microparticles to refill following implantation. The resulting antimicrobial activity of the refilled PMMA cement has the potential to serve as an additional window of therapy beyond that of what is obtained with PMMA cement with CD microparticles that is initially filled with RMP upon curing. When taken in combination, the duration of antimicrobial activity of PMMA beads with RMP-CD microparticles is substantially increased compared to the duration of activity that is obtained with clinically used formulations (i.e., gentamicin or tobramycin freely added in PMMA), and has the potential to treat advanced and chronic orthopedic infections. [42] [43] [44] Furthermore, the refillability property makes the PMMA cement with CD microparticles conducive toward potential lifelong treatment of recurrent infections. Since many recurrent infections may not present until several months following the end of the initial infection, it is often difficult for surgeons to locally deliver additional antibiotics from the implanted PMMA, as a result, the standard of care is to systemically administer antibiotics. [45] If the recurrent infection still persists, it is often necessary to remove the implanted device and perform a surgical debridement. Additionally, these infections can be particularly challenging to treat if a biofilm has developed. Since prior work has shown the ability of CD to be refilled with antibiotics even in the presence of biofilm, [34] PMMA with CD microparticles is an ideal candidate for the treatment of recurrent infections since it has the ability to be refilled with additional antibiotics following implantation and through biofilm, minimizing the risk of implant removal as well as the need for systemic antibiotics. Furthermore, our system is expected to be long-lasting in vivo, unaffected by any degradative processes upon implantation, and, thus, durable for long-term antibiotic refilling applications. PMMA bone cement is typically used as a nondegradable implant material [46] and CD microparticles have been shown to have longterm in vivo stability (out to at least 28 d). [47] Additionally, our drug release study samples did not display any indication of degradation after nearly 60 d in solution. Figure S2 Results from the compression testing (Table 1 ) and wateruptake study ( Figure S3 , Supporting Information) corresponded well, suggesting that water-uptake might be used as an indirect predictor for compressive strength of PMMA. These two factors appeared to have the following relationship: the larger the water uptake of a PMMA formulation, the lower its compressive strength. This observation held for all conditions analyzed with compressive testing. The relative porosity of PMMA samples was quantified using micro-computed tomography (micro-CT; Figure S4 , Supporting Information). The formation of pores in the PMMA cylinders was attributed to several different sources. One potential source of pores was hypothesized to be from human variability during hand-mixing and finger-packing of the cement-a factor also present in surgical settings. [48] Another unavoidable source of pores was from the volumetric shrinkage of the cement as it cured within the physical constraints of the mold.
Incorporation of free RMP in PMMA cylinders resulted in a cement that more closely resembled an elastomeric material rather than the hard cement formed after incorporation of RMP in CD microparticles (both 5 and 10 wt%). The poor mechanics of PMMA with free RMP are attributed to free RMP acting as a plasticizer. It is hypothesized that the carbonyl groups of RMP act to increase the free volume between PMMA chains. [49] As a result, RMP is able to block interactions between adjacent PMMA chains, promoting their relative mobility and decreasing the strength of PMMA. [49] The increased strength of the PMMA cylinders upon addition of RMP-CD microparticles is hypothesized to result from the inclusion complex formed between CD and RMP. While RMP is complexed with CD, CD is able to block the plasticizing groups of RMP from interacting with PMMA polymer chains, thus inhibiting the plasticization effect. As a result, the cement retains its inherent mechanical strength. A limitation of this study was that the experimental design did not allow elucidation of the mechanism behind this phenomenon.
Interestingly, incorporation of RMP into CD microparticles strengthened PMMA cylinders beyond values obtained for PMMA cylinders with empty CD microparticles. This phenomenon is hypothesized to be due in part to RMP complexation preventing the collapse of CD molecular "pockets" upon compression, thereby making the polymerized CD microparticles filled with drug stiffer.
Considering the increased duration of antimicrobial activity relative to clinically used formulations (60+ days), refilling capabilities (30-40 d additional activity), and compressive strength (∼76 MPa) of cement with 10 wt% RMP-β-CD microparticles, we envision that our cement formulation could be applied in several different clinical scenarios. The inherent mechanical strength of our bone cement formulation, relative to clinical antibiotic formulations, suggests that our cement could be used for weight or load-bearing applications such as in total knee or hip replacements. Since bone cement is most frequently used with total knee replacements, rather than hip replacements, [50] we envision that our cement will be more physically accessible in knee replacements for antibiotic refilling purposes. During arthroplasties, the bone cement is typically packed into the medullary cavity of the bone which is in contact with the vasculature of the trabecular bone. If a bolus of antibiotic is to be injected locally near the blood supply, the implanted cement has the potential to be refilled. We hypothesize that the drug could be directly infused into the medullary canal using existing clinical techniques such as tibial intraosseous infusion. [51] Alternatively, if antibiotic refilling is difficult in these applications, our cement may lend itself more toward an antibiotic bead formulation (similar to STIMULAN beads or those used in treatment of other nonorthopedic infections [52] ) or temporary spacer in a two-part revision surgery where it may be more accessible to locally administer antibiotic for refilling.
One limitation of the study was the relatively low concentration of antibiotic freely added into the bone cement. In an effort to account for the poor mechanics of PMMA with free RMP we incorporated a relatively low amount of drug (1.25% wt/wt drug/cement) and subsequently incorporated the same low amount of each of the other antibiotics into the samples. Since upward of 5% wt/wt drug/cement may be used in clinical cases, it is possible that gentamicin and tobramycin may demonstrate an increased antimicrobial activity in PMMA then what we observed with 1.25% drug. Nevertheless, the duration of antimicrobial activity in PMMA that we observed from cement with 10 wt% RMP-β-CD microparticles well surpassed the duration of activity observed in cement with concentrations of gentamicin or tobramycin even beyond those used clinically. [22] Future studies will examine the localization of antibiotic refilling, specifically how deep the RMP penetrates beneath the surface of the cement with CD microparticles and how refillability changes over time (i.e., 6 months, 1-2 years). Additionally, the drug release kinetics, antimicrobial activity, refilling properties, and mechanical properties of higher weight percentages of CD microparticles in PMMA will be analyzed (e.g., 15 wt%), given that the cement had ample strength and favorable effectiveness against S. aureus at the 10 wt% RMP-β-CD microparticle concentration.
Conclusion
Through this study it was demonstrated that the addition of up to 10 wt% CD microparticles to PMMA bone cement allows for a more consistent and prolonged duration of antimicrobial activity with antibiotics, such as RMP (compared to when the antibiotic is freely incorporated into the cement) while preserving the mechanical properties of the PMMA. Simultaneously, the addition of 10 wt% CD microparticles enables the PMMA to be refilled with antibiotics following implantation for additional windows of therapeutic activity. The combined duration of antimicrobial activity resulting from PMMA with 10 wt% CD microparticles that are initially filled and later refilled with RMP is nearly 100 d making the formulation a potential candidate for the treatment of chronic or recurrent orthopedic infections. RMP cannot currently be added freely into bone cement due to the severe detriment the drug has on cement compressive strength. However, our formulation with RMP-filled CD microparticles retains cement compressive strength. Therefore, through the addition of CD microparticles to cement, a wider range of antibiotics (beyond traditional aminoglycosides and glycopeptides) may potentially be used with PMMA than are currently compatible. Furthermore, since the addition of up to 10 wt% RMP-CD microparticles resulted in comparable ultimate compressive strength to that observed with PMMA with free tobramycin, there is potential for PMMA formulations with CD microparticles to be used in weight-bearing applications.
Experimental Section
Materials: Lightly epichlorohydrin cross-linked β-and γ-CD prepolymers (116 kDa molecular weight) were purchased from CycloLab (Budapest, Hungary). Ethylene glycol diglycidyl ether was purchased from Polysciences Inc. (Warrington, PA). Rifampicin (RMP) was purchased from Research Products International (Mt. Prospect, IL). Gentamicin and tobramycin were purchased from Fisher Scientific (Pittsburgh, PA). Simplex HV (high viscosity) radiopaque bone cement from Stryker Orthopaedics (Mahwah, NJ) was kindly provided by Dr. Mathias Bostrom (Hospital for Special Surgery, NY). Green fluorescent protein (GFP)-labeled S. aureus stock culture was kindly provided by Dr. Edward Greenfield (Case Western Reserve University, OH). PTFE stock for cylindrical specimen molds was purchased from McMaster-Carr (Aurora, OH). All other reagents and solvents were purchased from Fisher Scientific in the highest grade available.
Synthesis of Insoluble Polymerized Cyclodextrin (β-and γ-CD Microparticles): 1 g of lightly cross-linked epichlorohydrin CD (β-or γ-CD) was dissolved in 4 mL of 0.2 m potassium hydroxide. 1.6 mL of ethylene glycol diglycidyl ether cross-linker was added to the dissolved polymer and the solution was vortexed for 2 min. The polymer solution was poured into a heated mixture (60 °C) of 50 mL light mineral oil with a 500 µL mixture of Tween 85 (24%) and Span 85 (76%) stirred at 1000 rpm. The emulsion was heated at 60 °C for 4 h. Microparticles were serially washed and centrifuged (600 rpm, 5 min) with solvents of gradually increasing polarity (2× each with light mineral oil, hexanes, acetone, MilliQ water). Washed microparticles were frozen with 35 mL MilliQ water and lyophilized for 3 d. Dried microparticles were stored in a desiccator prior to use in further experiments. Average microparticle diameter has been established as 250 µm using this protocol in previous work. [47] Synthesis of Insoluble Polymerized Cyclodextrin (β-CD) Disks: Polymerized β-CD disks were synthesized according to a previously established protocol. [30] Briefly, 1 g of β-CD prepolymer was dissolved in 4 mL DMF and cross-linked with hexamethylene diisocyanate (HDI) in a molar ratio of 1:0.16 (glucose residue:HDI). The solution was cured at 70 °C for 45 min and punched into 6 mm disks. Disks were sequentially washed over several days using 100% DMF, 50:50 DMF:MilliQ water, and 100% MilliQ water to remove unreacted DMF and prepolymer.
Microparticle Drug Filling: 40 mg samples of β-or γ-CD microparticles were placed in 1.5 mL Eppendorf tubes and filled with 1 mL of 5 mg mL −1 of RMP in DMF or 1 mL of 15 mg mL −1 of tobramycin and gentamicin in phosphate buffered saline (PBS). Samples were placed in a rotisserie shaker for 3 d at room temperature, centrifuged for 8 min, and washed with MilliQ water (RMP: 3×; tobramycin and gentamicin: 1×). Washed microparticles were frozen and lyophilized for 3 d. Dried drug-filled microparticles were stored in a desiccator prior to use in further experiments.
Synthesis of PMMA Spherical Beads and Cylinders: 4 g samples of Simplex HV surgical grade bone cement powder were reacted at room temperature with 2 mL of methyl methacrylate monomer for each batch of PMMA cement, according to manufacturer instructions. Upon adding the liquid monomer, each antibiotic (1.25% wt/wt gentamicin, tobramycin, or RMP/cement) or insoluble polymerized CD empty and drug-filled microparticles (β-or γ-CD, 5 or 10 wt%, ≈250 µm diameter microparticles) were hand-mixed into the PMMA mixture until a soft dough formed. PMMA dough containing CD microparticles was pressed into a thin sheet and formed into 6 mm spherical beads, and dried at room temperature. Spherical bead samples were used in zone of inhibition, drug release, water uptake, and agarose refilling studies.
Cylindrical samples were fabricated and tested in accordance with ASTM F451-16. [53] Bone cement was formed into cylindrical samples 6 mm in diameter and 12 mm in height with the use of custommachined two-part PTFE molds (see Figure S5 , Supporting Information). Uncured cement dough was hand-mixed and firmly finger-pressed into the cylindrical wells of the PTFE molds. Cement dough was allowed to cure for a minimum of 1 h prior to removal of the solidified specimens from the molds. Samples were visually inspected and only samples that contained no visible defects larger than 0.5 mm in major diameter were considered for testing. Both ends on each sample were sanded flat and smooth using wet 240 grit (P280) silicon carbide sandpaper maintained perpendicular to the cylinder axis. Individual samples were weighed and their dimensions were measured (length and diameter) www.advancedsciencenews.com www.advhealthmat.de to the nearest 0.01 mm using digital calipers prior to testing for determining stress and strain, with diameter taken at the cylinder midlength. Due to equipment scheduling constraints, samples were tested between 43 ± 5 h after initial mixing, being stored in ambient conditions prior to testing (20.5-21.7 °C and 30-50% relative humidity). Groups of cylindrical samples included pure PMMA cement and cement with free tobramycin, free RMP, empty 5 wt% β-CD microparticles, empty 10 wt% β-CD microparticles, 5 wt% RMP-β-CD microparticles, and 10 wt% RMP-β-CD microparticles. Cylindrical samples were used in micro-CT scans and compression testing. Serial Plate Zone of Inhibition Study: PMMA spherical beads (6 mm diameter) with antibiotic freely added in (1.25% wt/wt drug/cement powder: gentamicin, tobramycin, RMP) and PMMA spherical beads with either 5 or 10 wt% β-or γ-CD microparticles filled with each of the three antibiotics were placed on the center of a Trypticase soy agar plate with 70 µL of S. aureus culture. [30] Each condition was repeated in triplicate. Agar plates were incubated at 37 °C overnight and the zones of bacterial clearance surrounding each drug filled PMMA spherical bead were measured (from the edge of the bead to the edge of the bacterial clearance) using calipers and averaged. PMMA spherical beads were transferred to a freshly seeded agar plate and the measurement process was repeated until the zones of clearance were no longer visible.
Quantification and Activity of Drug Release Aliquots: Drug filled PMMA spherical beads with each of the three antibiotics (with and without CD microparticles) were placed in 1 mL of release solution (PBS: gentamicin and tobramycin; or PBS with 10% DMF: RMP) and agitated at 37 °C. Due to the hydrophobic nature of RMP, a hydrophobic sink (DMF) was added to the release media. After set time points (2 h, 4 h, 1 d, 2 d, etc.) the entire release solution (1 mL) was removed and replaced with 1 mL fresh solution to maintain infinite sink conditions. Drug concentration in the release solution was quantified using 200 µL samples of release media with UV absorbance spectroscopy (400 nm: gentamicin and tobramycin; 473 nm: RMP) using a Biotek 96 well plate reader (H1: Winooski, VT). In order to quantify gentamicin and tobramycin with absorbance spectroscopy, a ninhydrin reaction was performed prior to scanning the samples. [54, 55] Specifically, 120 µL of 2 mg mL −1 ninhydrin solution in PBS was added to 400 µL of each of the gentamicin or tobramycin release samples, heated at 95 °C for 15 min (tobramycin) or 25 min (gentamicin), cooled, and read at 400 nm absorbance. [54, 55] Drug concentrations were determined using standard curve.
The subsequent antimicrobial activity at each time point for the drug release samples (each aliquot) was also evaluated against S. aureus. A 6 mm filter paper disk was soaked in each drug release aliquot solution and a zone of inhibition study was carried out for a period of 1 d against S. aureus. [37] This experiment enabled the antimicrobial activity of each release aliquot to be compared to the amount of drug released at a given time point to ensure that the amount of drug being released exceeded the minimum inhibitory concentration.
Water-Uptake Study: Nondrug filled, drug filled (three different antibiotics), and CD microparticle embedded (β-and γ-CD, 5 and 10 wt%) PMMA spherical beads were initially weighed (within a week of synthesis) in triplicate and placed in 4 mL of MilliQ water at 37 °C under agitation. After 2 h, beads were briefly dried and reweighed. Beads were placed back in 4 mL MilliQ water and were reweighed after 3 d. Intrabatch variance in the water uptake of the PMMA beads was calculated after both 2 h and 3 d.
Micro-CT Scans and Porosity Quantification: Cylindrical specimens (prior to performing compression tests) were individually placed into 15 mL polypropylene centrifuge tubes and scanned in a Siemens Inveon PET-CT scanner (Siemens Medical Solutions, Malvern, PA) operated with a PC using Siemens Inveon Acquisition Workplace software with identical scan settings (medium-high magnification, binning factor 1, 80 kV, 500 µA, 448 ms exposure, 200 ms settle, noncontinuous rotation, 512 steps, 360° rotation, 14.21 µm effective pixel size) and reconstruction settings for all specimens. Data was exported into DICOM format using Siemens Inveon Research Workplace software and cement pore segmentation/thresholding, thresholding of solid fraction, and model export was performed using 3D Slicer software (BWH and 3D Slicer contributors, version 4.8). [56] An upper threshold CD unit value of −200 was used for thresholding/segmentation of pores. A lower threshold CD unit value of 0 (which corresponds with water on the Hounsfield scale) was used for thresholding of the solid fraction. Values were decided based on visual inspection and the reasoning that the radiodensity of cement solids is higher than liquid water. Volumetric measurement of exported models was performed using Netfabb Standard 2018 software (Autodesk, Inc.). Pore volume was expressed as a percentage of the total volume on which segmentation was performed.
Compression Testing: Cylindrical PMMA samples (micro-CT scanned in previous section) were loaded in compression at 20 mm min −1 on a mechanical testing frame (Material Testing System MTS 810, MTS Systems Corporation). Data were sampled at 200 Hz and analyzed for ultimate load, ultimate compressive strength, stiffness, compressive modulus, strain to ultimate load, and work to ultimate load. For free RMP samples because of the lack of local maxima beyond the elastic limit in their load-displacement curves, ultimate load was defined as 2.0% offset load. For all other groups, ultimate load was defined at the local maxima beyond the elastic limit in load-displacement curves.
PMMA Antibiotic Refilling in Agarose Study: Tissue-mimicking agarose models were created according to a previously established protocol. [34] Briefly, 0.075 wt/vol% agarose was dissolved in PBS and brought to a boil. 5 mL of the hot agarose was added to each well of a Costar 6-well cell culture plate (Corning Life Sciences, Corning, NY). Once the agarose solidified, a single PMMA spherical bead (with or without CD microparticles) and a polymerized β-CD disk were placed on top of the agarose. An additional 5 mL of hot agarose was placed on top and allowed to set at room temperature. A 6 mm well was punched into the center of the agarose above the implanted sample(s). Background absorbance signals were collected using a 19 × 19 point area scan on a Biotek 96 well plate reader for each sample (400 nm: tobramycin and gentamicin; 473 nm: RMP). 100 µL of drug solution (6 mg mL −1 in methanol: RMP) was injected into the preformed well in the agarose and the samples were covered and agitated at 37 °C for 48 h. After 24 and 48 h, area absorbance scans were collected. Drug filled PMMA bead implants were removed from the agarose after 48 h and placed on a freshly seeded S. aureus agar plate to evaluate their antimicrobial activity using a zone of inhibition study. Each condition was repeated in triplicate.
Quantification of Antibiotic Refilling Efficiency: PMMA spherical beads filled with drug (with and without CD microparticles) of each of the three antibiotics from the agarose refilling study (from section above) were placed in 4.2 mL of DMF and agitated at 37 °C overnight in an effort to leach out all of the filled drug. Antibiotic solution from the dissolved PMMA spherical beads was diluted and the concentration of each drug was quantified using absorbance spectroscopy and standard curves.
Statistical Analysis: All data were displayed as the mean of each condition tested in triplicate (zone of inhibition, drug release, wateruptake, micro-CT, agarose refilling) or n ≥ 7 (compression testing) with the standard deviation as the error bars. Statistical analysis tests were carried out in Microsoft Excel 2016. A two-tailed Student's t-test with unequal variances was used to evaluate the zone of inhibition (n = 3), water uptake (n = 3), and RMP agarose refilling (n = 3) data. A one-tailed Student's t-test with unequal variances was used to evaluate the compressive strength (n = 7) and micro-CT porosity quantification (n = 3). T-test p values < 0.05 were considered to be statistically significant.
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